Page 20 - End Results Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zolbetuximab is an investigational first-in-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

BRUKINSA is the only Bruton's Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA (ibrutinib) in relapsed/refractory CLL. BRUKINSA also showed superiority to chemoimmunotherapy

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)BRUKINSA is the only Bruton’s Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA® (ibrutinib) in relapsed/refractory CLL.BRUKINSA also showed...

Talicia's efficacy, in this analysis of pooled data from two Phase 3 studies, was unaffected by presence of diabetes or elevated body mass index (BMI);...

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLLIf approved, BRUKINSA would be the only BTK inhibitor for CLL in the European Union to achieve superior efficacy versus standard of care in head-to-head trialsWith significantly lower rates of atrial fibrillat...